FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Mammal patents



      
           
This page is updated frequently with new Mammal-related patent applications. Subscribe to the Mammal RSS feed to automatically get the update: related Mammal RSS feeds. RSS updates for this page: Mammal RSS RSS


Compositions and methods for enhancing antigen-specific immune responses

Compositions and methods for enhancing antigen-specific immune responses

Compositions and methods for enhancing antigen-specific immune responses

Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or…

Date/App# patent app List of recent Mammal-related patents
07/02/15
20150184165
 Immunosuppression compound and treatment method patent thumbnailnew patent Immunosuppression compound and treatment method
A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed ctla-4 mrna region identified by seq id no: 22 in seq id no: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mrna of the subject.
07/02/15
20150184138
 Plant-based recombinant butyrylcholinesterase production methods patent thumbnailnew patent Plant-based recombinant butyrylcholinesterase production methods
A new, reliable, easily scalable and reproducible method for the production of recombinant butyrylcholinesterase (rbuche) is provided. Through the utilization of a plant transfection procedure, various plant strains have been shown to generate effective and scalable amounts of rbuche under acceptable manufacturing processes to permit reliable levels of such enzymes for desired nerve agent protection requirements (including tetrameric products).
07/02/15
20150183871
 Antibodies against the rgm a protein and uses thereof patent thumbnailnew patent Antibodies against the rgm a protein and uses thereof
The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize rgm a protein. Specifically, these antibodies have the ability to inhibit the binding of rgm a to its receptor and/or coreceptors.
07/02/15
20150183850
 Methods and compositions for treating amyloid deposits patent thumbnailnew patent Methods and compositions for treating amyloid deposits
The present disclosure provides methods of delivering a protective apoe isoform to the central nervous system of a mammal, comprising administering to the cerebrospinal fluid (csf) of the mammal an raav particle comprising an aav capsid protein and a vector comprising a nucleic acid encoding the protective apoe isoform inserted between a pair of aav inverted terminal repeats in a manner effective to infect ependymal cells in the non-rodent mammal such that the ependymal cells secrete the apoe into the csf of the mammal.. .
07/02/15
20150183843
 Glycoproteins having lipid mobilising properties and therapeutic applications thereof patent thumbnailnew patent Glycoproteins having lipid mobilising properties and therapeutic applications thereof
A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a zn-α2-glycoprotein, or of a fragment thereof having an apparent molecular mass mr greater than 6.0 kda as determined by gel exclusion chromatography. Methods of isolation and purification from biological material are also disclosed together with uses of the material for making up pharmaceutical compositions, especially pharmaceutical compositions useful for treating mammals to achieve weight reduction or for controlling obesity.
07/02/15
20150182681
 Ambulatory lung assist device with implanted blood pump and oxygenator patent thumbnailnew patent Ambulatory lung assist device with implanted blood pump and oxygenator
The present disclosure provides a system for oxygenating blood. The system may include an implantable blood pump that may draw a supply of blood from the circulatory system of a mammalian subject, such as a human being.
07/02/15
20150182638
 Virus-mediated delivery of bevacizumab for therapeutic applications patent thumbnailnew patent Virus-mediated delivery of bevacizumab for therapeutic applications
The invention provides a method of inhibiting ocular neovascularization in a mammal by administering a composition comprising a bevacizumab-encoding adeno-associated virus (aav) vector directly to the eye of the mammal.. .
07/02/15
20150182637
 Widespread gene delivery of gene therapy vectors patent thumbnailnew patent Widespread gene delivery of gene therapy vectors
The present invention relates to improved compositions and methods for delivering and expressing therapeutic genes in mammals. More particularly, the invention stems from the unexpected discovery that a remarkable, massive and widespread therapeutic gene delivery and expression is obtained in mammals when a therapeutic gene is incorporated in a viral vector and administered both into the csf and into the blood of the mammal.
07/02/15
20150182636
 Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents patent thumbnailnew patent Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
The invention provides methods of preventing or treating diseases or disorders caused by biological agents or chemical agents in a subject (e.g., a mammal, such as a human) by administering genetically modified human umbilical cord perivascular cells.. .
07/02/15
20150182621
 Compositions and methods for enhancing antigen-specific immune responses patent thumbnailnew patent Compositions and methods for enhancing antigen-specific immune responses
Methods for treating or preventing recurrence of hyper proliferating diseases, e.g., cancer and persistent viral infections, are described. A method may comprise priming a mammal by administering to the mammal an effective amount of a nucleic acid composition encoding an antigen or a biologically active homolog thereof and boosting the mammal by administering to the mammal an effective amount of an oncolytic virus comprising a nucleic acid encoding the antigen or the biologically active homolog thereof..
07/02/15
20150182617
new patent

Glycoproteins for pseudotyping lentivectors


The invention relates to compositions and methods based on the use of viral g proteins to pseudotype vectors. The viral g proteins can be expressed by expression vectors and can be used to pseudotype lentiviral vectors.
07/02/15
20150182612
new patent

Compositions and methods for treating an active mycobacterium tuberculosis infection


The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active m.
07/02/15
20150182587
new patent

Methods for treating reperfusion injuries


The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin. .
07/02/15
20150182549
new patent

Method for enzymatic glycosylation of oligosaccharides from mammalian animal milk


A method for modifying galactosyl disaccharides in order to enhance their bifidogenic effect, comprising reacting at least one glycosyl donor with a precursor galactosyl disaccharide or a mixture of precursor galactosyl disaccharides using enzyme catalysis, compounds obtainable by said method and the use of such compounds in consumable products.. .
07/02/15
20150182515
new patent

Methods for treating obesity and disorders associated with hyperlipidemia in a mammal


The disclosure relates to methods for treating hyperlipidemia in a mammal. The present disclosure also relates to methods for treating and/or controlling obesity in a mammal.
07/02/15
20150182500
new patent

Compositions for use in treating or preventing metabolic stress-induced lung injury and methods for increasing physical capacity of mammalian livestock


The present invention relates to a composition comprising (i) choline and (ii) a compound selected from the group consisting of palmitate, vitamin c and vitamin e for use in treating or preventing metabolic stress-induced lung injury and a method for increasing physical capacity of mammalian livestock comprising administering to the mammalian livestock the above composition.. .
07/02/15
20150182453
new patent

Methods and compositions for enhancing the viability of microneedle pores


Described herein is a method of transdermally administering one or more pharmaceutically active agents to a mammal. The method comprises administering one or more active pharmaceutical agents to the skin of the subject, in conjunction with microneedles and one or more cox inhibitors, whereby the cox inhibitors facilitate the absorption of the active pharmaceutical agents by prolonging the pore opening created by the application of the microneedle..
07/02/15
20150182415
new patent

Eyelid care appliance


Disclosed herein is an improved eyelid care appliance and method of using such appliance for preventing and treating blepharitis and mammalian meibomian gland dysfunction caused by gland obstruction. The method and apparatus of the invention enable restoration and maintenance of eyelid hygiene and the natural flow of secretions from the meibomian glands.
07/02/15
20150181845
new patent

Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease


Systems and methods for screening whether a candidate compound inhibits delta-6 desaturase activity are disclosed. Also disclosed is a transgenic mammal which overexpresses a gene encoding delta-6 desaturase and an animal model of a cardiometabolic disorder or disease that includes the transgenic mammal.
06/25/15
20150177251

Method for detecting and/or assaying annexin a3 from a mammal in blood or at least one derivative thereof


Method and pack for detecting and/or assaying annexin a3 from a mammal in blood or at least one derivative thereof.. .
Biomérieux
06/25/15
20150176020

Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases


The present invention relates to non-mammalian β-1,4-galactosyltransferases that can be used in their wild-type or in modified forms. The invention further relates to transformed plants and plant cells expressing non-mammalian β-1,4-galactosyltransferases and methods to produce glycoproteins with altered and preferably mammalian-type glycosylation.
Stichting Dienst Landbouwkundig Onderzoek
06/25/15
20150176003

Euglobulin-based determining the biological activity of defibrotide


It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 iu/mg of defibrotide, preferably from 27.5 to 32.5 iu/mg and, more preferably, from 28 to 32 iu/mg..
Gentium S.p.a.
06/25/15
20150175960

Highly efficient methods for reprogramming differentiated cells and for generating animals and embryonic stem cells from reprogrammed cells


The present invention relates generally to the field of somatic cell nuclear transfer (scnt) and to the creation of cloned animals and cells. The disclosure relates to a method of cloning a mammal, obtaining pluripotent cells such as embryonic stem cells, or for reprogramming a mammalian cell using an oocyte and a fertilized embryo..
Advanced Cell Technology, Inc.
06/25/15
20150175959

Post-partum mammalian placenta, its use and placental stem cells therefrom


The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells.
Anthrogenesis Corporation
06/25/15
20150175952

Stirrer system


The present invention concerns a stirrer system for animal cell culture consisting of a combination of at least one radially-conveying stirrer element and at least one axially-conveying stirrer element, wherein at least three stirrer elements must be present and the uppermost stirrer element is an axially-conveying stirrer element. The stirrer elements are arranged at a certain distance above one another on a stirrer shaft.
Hoffmann-la Roche Inc.
06/25/15
20150175701

Ovr110 antibody compositions and methods of use


Isolated antibodies and antigen binding fragments thereof directed against ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an ovr110-expressing cancer cells and alleviating or treating an ovr110-expressing cancer in a mammal.
Diadexus, Inc.
06/25/15
20150175688

Production cell line enhancers


The present invention relates to discovery of the ectopic expression of edem2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the cho cell, containing recombinant polynucleotides encoding edem2.
Regeneron Pharmaceuticals, Inc.
06/25/15
20150175643

Oligosaccharide-protein conjugates


Provided herein are conjugates comprising a protein and an oligosaccharide of one of formulae i-vi. Also provided herein are pharmaceutical compositions comprising such conjugates.
Genzyme Corporation
06/25/15
20150175603

Tricyclic compounds as kat ii inhibitors


Compounds of formula (i), wherein r1, r2, x1, y1, z1, and z2 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.. .
Pfizer Inc.
06/25/15
20150175562

Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]


The invention provides modulators for the orphan nuclear receptor rory and methods for treating rory mediated diseases by administering these novel rory modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of formula (1), (1′), (100), (100′), (200) and (200′) and the enantiomers, diastereomers, tautomers, /v-oxides, solvates and pharmaceutically acceptable salts thereof..
Phenex Pharmaceuticals Ag
06/25/15
20150174294

Disease treatment via developing non-syngeneic graft transplantation


A method of providing a pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function to a mammalian subject is provided. The method comprises transplanting into the subject a developing mammalian pancreatic, lymphoid/hematopietic or pulmonary organ/tissue graft, respectively, thereby generating a functional pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue, respectively, for providing the pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function, respectively, to the subject..
Yeda Research And Development Co. Ltd.
06/25/15
20150174266

Aprotinin polypeptides for transporting a compound across the blood-brain barrier


The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates.
Angiochem Inc.
06/25/15
20150174242

Monovalent anti-cd3 adjuvants


This document provides methods and materials related to using monovalent anti-cd3 antibodies (e.g., monovalent anti-cd3 fab fragments) as adjuvants to increase the immune response produced against an antigen (e.g., a tumor associated antigen). For example, vaccine compositions containing monovalent anti-cd3γε fab fragments in combination with tumor associated antigens (e.g., tumor associated antigens having little or no immunogenicity in the absence of monovalent anti-cd3γε fab fragments) alone or in combination with adjuvants for signals two and/or three required for full activation of t cell immune function, as well as methods and materials for using monovalent anti-cd3γε fab fragments to increase the immune response produced against an antigen (e.g., a tumor associated antigen) within a mammal (e.g., a human) are provided..
Mayo Foundation For Medical Education And Research
06/25/15
20150174240

Novel veterinary vaccine


The present invention relates to novel compositions for inducing an immune response in mammals. The composition preferably comprises an antigen and a lipopolysaccharide in an oil-in-water formulation.
06/25/15
20150174203

Compositions and methods for modulating pro-inflammatory immune response


Provided herein are compositions and methods useful for increasing a pro-inflammatory immune response, treating an autoimmune disorder, inflammation, or transplant rejection in a mammal by activating a leukocyte immunoglobulin-like receptor (lilr) protein. Also provided are compositions and methods useful for increasing a pro-inflammatory immune response, treating cancer, and treating infectious disease in a mammal by blocking the activation of a lilr protein..
The Board Of Regents, The University Of Texas System
06/25/15
20150174192

Pea protein peptides with anti helicobacter pylori activity


The invention relates to a composition comprising pea protein hydrolysate for the treatment and/or prevention of infection by gastrointestinal pathogens, in particular helicobacter pylori and/or a disease associated with infection by said gastrointestinal pathogen in mammals.. .
N.v. Nutricia
06/25/15
20150174191

Pharmaceutical composition for treating hyperproliferative diseases


The present invention relates to the field of biotechnology and medicine, in particular to a pharmaceutical composition having an antiproliferative activity and comprising an chimeric peptide and to a method of treating oncologic diseases, which includes introducing the chimerical peptide into a mammal requiring such treatment. The objective of the of invention is the development of a preparation that effectively penetrates the target cells and has a high cytostatic and cytotoxic activity..
Ooo "metamax"
06/25/15
20150174187

Topical treatment compositions comprising benzoin and olive fruit extract


Disclosed are treatment compositions adapted for application to mammalian skin, which treatment compositions are effective initiators for the generation of human keratinocytes on or within the treated skin, particularly in the locus of the skin wherein the treatment composition has been applied, which treatment composition comprises benzoin and an olive oil extract which contains hydroxytyrosol and/or hydroxytyrosol. In certain preferred embodiments the benzoin and the olive oil extract and/or hydroxytyrosol are microencapsulated..
06/25/15
20150174174

Placental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells


The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations.
Anthrogenesis Corporation
06/25/15
20150174148

Use of nicotinamide riboside to treat hearing loss


The invention provides a method of preventing or treating hearing loss in a mammal in need thereof. The method involves administering to the mammal an agent that increases intracellular nad+ in the mammal.
Cornell University
06/25/15
20150174123

Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury


A method of reducing reperfusion injury in mammalian tissue comprising contacting the tissue with a protein phosphatase 2a (pp2a) inhibitor having the structure:. .
Lixte Biotechnology, Inc.
06/25/15
20150174058

Use of moss to improve dental health


A method of improving dental health in a mammal in which a mammal drinks at least 0.5 liters of water per day for a majority of the days of a period of at least one month, the water having been contacted with an amount of a non-decomposed moss effective to improve dental health as evidenced by a reduction in the pocket depths of the teeth of the mammal. A method of improving dental health in a mammal in which the mammal's teeth are brushed using a toothpaste or rinsed with a mouthwash for a majority of the days of a period of at least one month, the toothpaste or mouthwash containing an amount of a non-decomposed moss or non-decomposed moss extract effective to improve dental health as evidenced by a reduction in the pocket depths of the teeth.
Embro Corporation
06/25/15
20150173795

Devices, systems, and methods for delivering a substance within a mammalian luminal organ or area adjacent thereto


Devices, systems, and methods for delivering a substance within a mammalian luminal organ or area adjacent thereto. In at least one exemplary embodiment of a system of the present disclosure, the system comprises an inner delivery device, comprising an inner portion configured to receive a substance therein, a pock tip at or near a distal end of the inner delivery device, the pock tip configured to deliver the substance from the inner portion, through a pock tip aperture defined within the pock tip, and into a mammalian tissue and/or luminal organ, and an embolus positioned within the inner portion, the embolus configured so that the substance remains distal to the embolus when the substance is positioned within the inner portion..
Cvdevices, Llc
06/18/15
20150168416

Kits for detecting and monitoring endocrine disrupting chemicals (edcs)


Described herein are compositions, methods, a system, and kits for detection of endocrine disruptor chemicals (edcs) in environmental and other samples, such as samples of water including but not limited to waste water treatment plant effluent, using a live-cell fluorescence-based nuclear translocation reporter system. Upon binding of a ligand to a fluorescent-labeled reporter protein, the protein (and therefore the fluorescence) is translocated in a ligand level-dependent manner from the cytoplasm to the nucleus of live mammalian cells; this translocation is detectable as diffuse (cytoplasmic) fluorescence converting to localized, brightly fluorescent nuclei.
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
06/18/15
20150168382

Methods and reagents for evaluating the binding of mammalian sperm


The present invention provides a new apparatus/system for determining fertility of mammalian sperm based on a specific sperm-binding test that mimics sperm binding to an egg. The inventive apparatus/system comprises surface-modified beads with a compound or conjugates containing a carbohydrate sequence associated with the mammalian zona-pellucida (zp) glycoproteins..
The Curators Of The University Of Missouri
06/18/15
20150167043

Nanofluidic device for isolating, growing, and characterizing microbial cells


Nanofluidic devices and methods of the invention are capable of autonomously isolating individual microbial cells using constrictive channels and growing monocultures of the cells for automated characterization of their biochemical properties and interactions with mammalian cells. Single microbial cells, such as bacterial cells, are isolated directly from environmental sources and cultured using chemical factors from their native environment..
Northeastern University
06/18/15
20150167001

Novel repressor on ifn-lambda promoter and sirna against gata1, evi1, and crx to alter ifn-lambda gene activity


The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the ifn-λ1 promoter. The present invention provides a method of using sirnas against zeb1 (binds to the repressor region) and blimp-1 (binds outside the repressor region) and increases the promoter activity of ifn-λ1 (i.e., increases the production of ifn-λ1 protein).
Medical Diagnostic Laboratories, Llc
06/18/15
20150166958

Brown fat cells and preparing same


This invention provides a method for preparing a brown adipocyte from a somatic cell of a mammal by introducing at least one brown adipocyte-related gene or expression product thereof and at least one reprogramming-related gene or expression product thereof into the somatic cell, the brown adipocyte-related gene being at least one member selected from the group consisting of prdm16(p) and c/ebpβ(c), the reprogramming-related gene being at least one member selected from the group consisting of myc family genes (c-myc(m), n-myc, l-myc(l), s-myc, and b-myc), glis family genes (glis1 (g), glis 2, and glis 3), klf family genes (klf1, klf2, klf3, klf4(k), klf5, klf6, klf7, klf8, klf9, klf10, klf11, klf12, klf13, klf14, klf15, klf16, and klf17), oct family genes, sox family genes, and lin-28.. .
Kyoto Prefectural Public University Corporation
06/18/15
20150166646

Methods and compositions for treating or diagnosing melanoma


Methods and compositions are provided for treating melanoma in a mammalian subject by reducing, inhibiting or down-regulating tumor-associated macrophage (tam) production or activity in the subject. The methods can involve a combination of reducing macrophage production and number while administering an anti-cancer therapy.
The Wistar Institute Of Anatomy And Biology
06/18/15
20150166634

Soluble tnf receptors and their use in treatment of disease


The present invention relates to tumor necrosis factor (tnf) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (tnfrs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to tnf and prevent tnf from signaling to cells.
Roche Innovation Center Copenhagen A/s
06/18/15
20150166621

Cell penetrating peptides to target eif4e


The present invention provides compounds to disrupt the eif4e-eif4g interaction and pharmaceutically acceptable salts of such compounds. Generally, the compounds are cell-penetrating peptides which bind mammalian initiation factor eif4e (cpp-eif4e), wherein the peptide comprises an amino acid sequence selected from the group consisting of seq id nos: 7, 9-11, 12-26, 27-44 and 45-51.
Hoffmann-la Roche Inc.
06/18/15
20150166609

Fusion expression of g-protein coupled receptor


The present invention relates to fusion proteins for the expression of g-protein coupled receptor proteins (gpcr) with the fusion partners, as inserted fragments, from mammalian cells. The fusion partners are from a fragment of apj protein (“the apj protein fragment”) or a fragment with homology of more than 90% similarity to the apj protein fragment; or a fragment of rgs16 protein (the “rgs16 protein fragment”) or a fragment with homology of more than 90% similarity to the rgs16 protein fragment; or the fragment of dnj protein (the “dnj protein fragment”) or a fragment with homology of more than 90% similarity to dnj protein fragment.
Viva Biotech (shanghai) Ltd.
06/18/15
20150166485

Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof


The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one benzimidazole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof..
Merial Limited
06/18/15
20150166477

Compounds for the treatment of mtor pathway related diseases


The present invention relates to compounds for the treatment of mtor (mammalian target of rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoactonitrile derivatives (aads) in the treatment of mtor pathway related diseases..
Newsouth Innovations Pty Limited
06/18/15
20150165228

Phototherapy patch with increased thermal insulation


The invention relates to alight emitting device (1) for application near mammal tissue (2), e.g. For the relief of pain, comprising: a flexible body (3) having a front surface (4) for facing the mammal tissue and an opposing back surface (5), said flexible body accommodating at least one light source (6), said at least one light source (6) is arranged for irradiating an irradiation area of said mammal tissue (2).
Koninklijke Philips N.v.
06/18/15
20150165018

Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals


The present invention is directed to a preferably live attenuated or subsequently inactivated african swine fever virus (asfv), comprising a non-functional genomic cd2 gene, wherein such asfv is non deficient in its replication, as well as to corresponding compositions or immunogenic compositions or vaccines, methods of production and uses for treating and/or preventing african swine fever in mammals, preferably of the family suidae, for instance pigs, more preferably domestic pigs (sus scrofa domesticus), wild pigs (sus scrofa scrofa), warthogs (potamochoerus porcus), bushpigs (potamochoerus larvatus), giant forest hogs (hylochoerus meinertzhageni) as well as feral pigs.. .
Consejo Superior De Investigaciones Cientificas, Csic
06/18/15
20150165008

Use of attenuated strains of parasites for the prevention or treatment of pathologies associated with an apicomplexan


Strains of sarcocystidae selected from toxoplasma spp or neospora spp isolated from their natural environment and having an immunostimulant effect, for the use thereof in the prevention or the treatment, in a mammal, of a pathology associated with an apicomplexan of the family cryptosporidiidae.. .
Universite Francois Rabelais De Tours
06/18/15
20150164953

Compositions and methods of treatment with stem cells


The disclosure of the present application provides compositions and methods of treatment with stem cells. In at least one embodiment of a method for treating a patient with an insulin-related disorder, the method comprises the step of administering a cell-based composition to a patient with an insulin-related disorder to treat the insulin-related disorder, the cell-based composition comprising at least one mammalian stem cell and optionally at least one islet cell, the at least one mammalian stem cell capable of prolonging an effective life of the at least one islet cell..
06/18/15
20150164926

Pharmaceutical compositions and treatment of mastitis


The present invention relates to a pharmaceutical composition and methods of treating and/or preventing mastitis in non-human mammals. More particularly, the present invention relates to the treatment of mastitis in cows.
Bayer Animal Health Gmbh
06/18/15
20150164912

Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors


Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .
06/18/15
20150164903

Method of using vasoconstrictive agents during energy-based tissue therapy


A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation.
Covidien Ag
06/18/15
20150164830

N-acetylcysteine amide (nac amide) in the treatment of diseases and conditions associated with oxidative stress


Methods and compositions comprising n-acetylcysteine amide (nac amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of nac amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione..
Sentient Lifesciences, Inc.
06/18/15
20150164784

Pouch-like structure with paracrine activity and its preparation


The present invention relates to a pouch-like structure useful for mechanically preventing distension and/or resisting dilation of the heart and for supporting the hearts function by controllable and paracrine support of a failing heart in a mammal. The pouch-like structure is composed at least partly of engineered tissue comprising genetically engineered cells, such as genetically engineered cells other than cardiac myocytes whereby said genetically engineered cells contain a gene encoding a paracrine factor, said gene encoding the paracrine factor being under control of an inducible promoter system or a heterologous promoter system.
Georg-august-universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaesmedizin
06/18/15
20150164670

Method for treating morbid obesity


A method for treating morbid obesity in a body of a mammal having a gastrointestinal tract extending through a stomach and a pyloric sphincter and a wall forming the stomach and pyloric sphincter. At least one implant is formed in the wall in the vicinity of the pyloric sphincter to inhibit emptying of the stomach..
Boston Scientific Scimed, Inc.
06/18/15
20150164635

Method of reducing the occurrence of macular and neuroretinal degenerations by alleviating age related retinal stresses as a contributing factor in a mammalian eye


A method of reducing the risk of macular degeneration is provided. The method includes inserting an intraocular collar stent into a portion of a mammalian eye, such that the stent is in contact with soft tissue of the anterior chamber.
Regeneye, L.l.c.
06/18/15
20150164554

Method for the controlled movement of motile cells in liquid or gaseous media


The invention concerns the domains of materials science and medicine and relates to a method such as can he applied to in vivo or in vitro fertilization, for instance. The problem addressed by the present invention is that of specifying a method with which the activity and controlled mobility of motile cells is improved and the absorption of materials alien to the cell is prevented as far as possible.
Leibniz-institut Fuer Festkoerper Und Werkstoffforschung Dresden E.v.
06/18/15
20150164053

Compositions and methods useful for making orthotopic tumors with controllable metastasis


Provided are compositions and methods that involve cancer cells which are modified so that they can form orthotopic tumors in a non-human mammal, and wherein metastasis of the tumor can be controlled. The cancer cells, which may be human cancer cells, are modified so that expression of a human chemokine receptor can be modulated.
Cornell University
06/11/15
20150159175

Methods and compositions for the targeted modification of a genome


Compositions and methods are provided for modifying a genomic locus of interest in a eukaryotic cell, a mammalian cell, a human cell or a non-human mammalian cell using a large targeting vector (ltvec) comprising various endogenous or exogenous nucleic acid sequences as described herein. Further methods combine the use of the ltvec with a crispr/cas system.
Regeneron Pharmaceutical, Inc.
06/11/15
20150159174

Methods and compositions for the targeted modification of a genome


Compositions and methods are provided for modifying a genomic locus of interest in a eukaryotic cell, a mammalian cell, a human cell or a non-human mammalian cell using a large targeting vector (ltvec) comprising various endogenous or exogenous nucleic acid sequences as described herein. Further methods combine the use of the ltvec with a crispr/cas system.
Regeneron Pharmaceutical, Inc.
06/11/15
20150159127

Mobile vessel or carrier for the manufacturing production, purification and sterile fill and finish of biologics


A mobile biologics production system can include a mobile carrier configured to be trailered to a biologics production location. The mobile carrier defines an interior volume configured to provide an aseptic environment for manufacturing, production, and purification of biologics.
Biocapacity On Demand, Llc


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.3073

2986

459474 - 0 - 71